Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FleuryBSP:FLRY3 -1.93%90 EV-to-EBIT is 8.03 as of Jul. 27, 2026, which is 39% below its 10-year median of 13.26. GuruFocus rates BSP:FLRY3 with a GF Score™ of 90/100 and a GF Value™ of R$17.53 (Fairly Valued). The stock has 5 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Fleury ranks better than 85.58% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Fleury's Enterprise Value is R$12,141 Mil.
Fleury's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was R$1,511 Mil. Therefore, Fleury's EV-to-EBIT for today is 8.03.
The historical rank and industry rank for Fleury's EV-to-EBIT or its related term are showing as below:
BSP:FLRY3'
s EV-to-EBIT Range Over the Past 10 Years
Min: 6.83 Med: 13.26 Max: 32.06
Current: 8.03
During the past 13 years, the highest EV-to-EBIT of Fleury was 32.06. The lowest was 6.83. And the median was 13.26.
BSP:FLRY3's EV-to-EBIT is ranked better than 85.58% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.47
vs BSP:FLRY3: 8.03
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Fleury's Enterprise Value for the quarter that ended in Mar. 2026 was R$11,962 Mil.
Fleury's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,511 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury EV-to-EBIT Related Terms
Fleury EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Fleury's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:FLRY3 vs TMO, DHR, IDXX: EV-to-EBIT Comparison
For the Diagnostics & Research subindustry, Fleury's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fleury's EV-to-EBIT falls into.
Fleury's current Enterprise Value is R$12,141 Mil.
Fleury's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,511 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury (BSP:FLRY3) has a EV-to-EBIT of 8.03 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fleury and its competitors. This is 39% below median its historical median of 13.26. Over the past decade, Fleury's EV-to-EBIT has ranged from 6.83 to 32.06. According to the industry distribution chart, Fleury ranks #15 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 14.4%.
Is Fleury's EV-to-EBIT too high?
Fleury's current EV-to-EBIT of 8.03 is 39% below median its 10-year median of 13.26. Over the past 10 years, this metric has ranged from a low of 6.83 to a high of 32.06. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.47. Fleury's value of 8.03 is 64.3% below this industry median. Based on the distribution chart, Fleury ranks #15 out of 104 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fleury has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fleury's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #15 out of 104 companies for EV-to-EBIT. This places Fleury in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 22.47. Fleury's value of 8.03 is 64.3% below this benchmark. Historically, Fleury's own EV-to-EBIT has ranged from 6.83 to 32.06 over the past decade. While the company's 10-year median is 13.26 vs. the industry median of 22.47, Fleury has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.47, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current EV-to-EBIT of 8.03 is 64.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fleury and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current EV-to-EBIT is 8.03, which is 39% below median its own 10-year median of 13.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Fairly Valued. The stock's GF Value™ is R$17.53, compared to a current price of R$16.26 — trading 7.2% below its estimated fair value. The current EV-to-EBIT is 8.03, which is 39% below median its 10-year median of 13.26 and 64.3% below the Medical Diagnostics & Research industry median of 22.47. Fleury's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current EV-to-EBIT is 8.03 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be undervalued.
The current stock price of R$16.26 is trading 7.2% below its estimated GF Value™ of R$17.53.
GuruFocus considers Fleury to be Fairly Valued.
Key valuation signals for BSP:FLRY3:
EV-to-EBIT: 8.03 (39% below median its 10-year median of 13.26)
GF Value™: R$17.53 vs. price of R$16.26 (7.2% below fair value)
Industry Position: 64.3% below the Medical Diagnostics & Research median (#15 of 104)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
90GF Score
Get the complete analysis for BSP:FLRY3
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
